Cybin Executives to Present at TD Cowen Neuropsychiatry Summit, Highlighting Breakthrough Mental Health Treatments

Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company, announced that Chief Medical Officer Amir Inamdar and Chief Business Officer George Tziras will participate in a fireside chat at TD Cowen’s 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit on September 17, 2025, at 9:20 a.m. ET. This presentation is significant as it provides a platform for Cybin to showcase its innovative approach to mental healthcare, particularly through its development of next-generation treatment options that address substantial unmet needs in neuropsychiatry.

The company is advancing CYB003, a proprietary deuterated psilocin analog, which is currently in Phase 3 studies for the adjunctive treatment of major depressive disorder. CYB003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, underscoring its potential to offer substantial improvements over existing therapies. This designation is a critical regulatory milestone that can accelerate the development and review process, highlighting the importance of Cybin's work in bringing novel treatments to market more efficiently.

In addition to CYB003, Cybin is developing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule, in a Phase 2 study for generalized anxiety disorder. The company's focus on deuterated compounds aims to enhance the pharmacokinetic properties of these molecules, potentially leading to more effective and durable results for patients. These developments are part of Cybin's broader research pipeline of investigational, 5-HT-receptor focused compounds, which target serotonin receptors involved in mood regulation and other neuropsychiatric functions.

The presentation at the TD Cowen summit matters because it provides visibility into Cybin's progress and the potential impact of its clinical programs on the mental health treatment landscape. With mental health conditions affecting millions worldwide and current treatments often yielding suboptimal results, Cybin's efforts to introduce novel drugs could address critical gaps in care. The company's operational presence in Canada, the United States, the United Kingdom, and Ireland further emphasizes its global reach and commitment to advancing neuropsychiatry research.

For more details, the full press release is available at https://ibn.fm/KXmrj. Updates relating to Cybin are also accessible in the company’s newsroom at https://ibn.fm/CYBN. This announcement underscores the importance of ongoing innovation in mental healthcare and Cybin's role in pioneering new therapeutic options that could transform patient outcomes in neuropsychiatry.